Meet Carlos Barcenas, M.D.
Carlos H Barcenas, M.D., M.Sc.
Department of Breast Medical Oncology, Division of Cancer Medicine
About Dr. Barcenas
Dr. Barcenas obtained his M.D. degree from the Pontiificia Universidad Javeriana in Bogota, Colombia in 1992. He specialized and practiced Occupational Medicine in Colombia until 1998. He then moved to Houston in 1999 and worked in the Department of Epidemiology at MD Anderson. He obtained a Master of Science degree in Epidemiology at The University of Texas School of Public Health in 2003. In 2009, he completed his training in the Internal Medicine Residency Program at the Medical College of Georgia, in Augusta. He then completed his Hematology-Medical Oncology Fellowship training at MD Anderson in June of 2013. He was appointed as Assistant Professor, Tenure Track, in the Department of Breast Medical Oncology at MD Anderson Cancer Center in July of 2013.
Read More
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Medical Director, Breast Cancer Survivorship, Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
Dr. Barcenas has a background in Epidemiology, and has worked in the field of Comparative Effectiveness and Health Outcomes Research, conducting various studies that have resulted in publications in several peer-reviewed journals. He has a strong research interest in Cancer Survivorship Research and has proposed studies designed to provide insight on environmental and genetic determinants of disease, to create risk prediction models, to assess the prevalence, mechanisms, risk factors and treatment of long-term treatment effects, with the ultimate purpose of enhancing the quality of life for cancer survivors.
Education & Training
Degree-Granting Education
| 2003 | University of Texas School of Public Health, Houston, Texas, US, Epidemiology, M.Sc |
| 1992 | Pontificia Universidad Javeriana, School of Medicine, Bogota, CO, Medicine, MD |
Postgraduate Training
| 2017-2018 | Faculty Development, The Heart of Leadership Program, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2010-2013 | Clinical Fellowship, Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2006-2009 | Clinical Internship, Internal Medicine, Medical College of Georgia, Augusta, Georgia |
| 1993-1997 | Specialist, Occupational Health, Universidad El Bosque, Bogotá |
Board Certifications
| 2013 | American Board of Internal Medicine - Medical Oncology |
| 2009 | American Board of Internal Medicine - Internal Medicine |
Experience & Service
Academic Appointments
Assistant Professor, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - 2019
Clinical Assistant Professor, Department of Medicine, Medical College of Georgia, Augusta, GA, 2009 - 2010
Administrative Appointments/Responsibilities
Quality Officer for Performance Improvement, Department of Ofc/EVP, Physician-in-Chief, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014 - 2016
Assistant Epidemiologist/Data Manager, Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1999 - 2006
Occupational Medicine Physician, Colmena Riesgos Profesionales, Bogotá, 1995 - 1998
Other Appointments/Responsibilities
Investigator, Breast Cancer Collaborative Outcomes Research Database (BC-CORD), Susan F. Smith Center for Women's Cancers at Dana Farber Cancer Institute, Boston, MA, 2014 - 2022
Institutional Committee Activities
Chair, Breast Medical Oncology Molecular Residual Disease Working Group, 2023 - Present
Committee Member, Breast PRO Committee Meeting, 2021 - Present
Chair and Program Committee Member, Survivorship and Database Working Group, 2021 - Present
Member, Clinical Care Work Group, 2019 - 2023
Member, MD Anderson Cancer Network, 2019 - Present
Team Member, Survival Outcomes Steering Taskforce, 2019 - 2019
Team Member, EHR EPIC Multidisciplinary Team Meeting for the Breast Center, 2018 - 2020
Collaborator, Global Program Business Development to assess research projects in Colombia, South America, 2018 - 2021
Team Member, Oncology History Advisory Group Meeting, 2017 - 2017
Committee Member, Medical Record Committee Meeting, 2016 - Present
Committee Member, Breast Cancer Related Lymphedema Core Leadership, 2015 - 2017
Team Member, Follow up for Validation on Breast Outcome Measures with ICCI Team, 2014 - 2017
Committee Member, Pain and End of Life Project Committee, 2014 - 2016
Committee Member, Patient History Data Base Ad-hoc Committee, 2014 - 2016
Member, Integrative Health Working Group, 2014 - 2017
Committee Member, Cancer Survivorship Research Advisory Workgroup, 2014 - 2023
Chair and Committee Member, Breast Cancer Management System (BCMS) Database Development Committee, 2014 - Present
Committee Member, Breast Program Leadership Committee, 2014 - 2020
Chair and Program Committee Member, New Patient Tumor Board Peer Review Planning Meeting, 2014 - Present
Honors & Awards
| 2016 | Distinguished Educator Award, Perspectives in Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center |
| 2016 | Paul Calabresi Career Development Award for Clinical Oncology (NIH K-12), Paul Calabresi |
| 2013 | Annual Hematology and Oncology Fellowship Clinical Investigation Award, The University of Texas MD Anderson Cancer Center |
| 2013 | MD Anderson Fellowship Education Chief Academic Year 2012 - 2013, The University of Texas MD Anderson Cancer Center |
| 2012 | Sheskey Family Fellowship for Breast Cancer Research Award |
| 2011 - 2013 | Allison and Brian Grove Endowed Fellowship |
| 2011 - 2013 | Fellow CERCIT Fellowship Scholar |
| 2011 | ASCO Annual Meeting Merit Award, American Society of Clinical Oncology |
| 2009 | First Place Rahn-Peacock Research Award, Medical College of Georgia |
| 2009 | Nominated for Resident of the Year, Medical College of Georgia |
| 2005 | Performance Reward. Department of Epidemiology, The University of Texas MD Anderson Cancer Center |
| 1997 | Evaluation of audiometric interpretation scales for the early detection of neurosensory hypoacusis by noise: Student Award Presentation in the Fifth Institutional Research Meeting of Schools of Medicine, Bogotá, Colombia |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Raghavendra AS, Bassett R Jr, Damodaran S, Barcenas CH, Mouabbi JA, Layman R, Tripathy D. Clinical Characteristics and Survival Outcomes of Metastatic Invasive Lobular and Ductal Carcinoma. JAMA Netw Open 8(4):e251888, 2025. e-Pub 2025. PMID: 40293750.
- Ali A, Koutroumpakis E, Song J, Booser D, Barcenas CH, Tripathy D, Barac A, Palaskas NL, Deswal A. Risk Stratification for Trastuzumab-Induced Cardiac Dysfunction and Potential Implications for Surveillance. JACC CardioOncol 7(3):203-215, 2025. e-Pub 2025. PMID: 40246379.
- Shin-Cho, LJ, Choi, E, Dawkins-Moultin, L, Wong, CY, Borjas, M, Fei, F, Xu, Y, Chen, M, Barcenas, CH, Li, Y, Lu, Q. Feasibility and acceptability of an online expressive writing intervention for rural breast cancer survivors. European Journal of Oncology Nursing 74, 2025. e-Pub 2025. PMID: 39813977.
- Barcenas CH. Clinical characteristics and survival outcomes of metastatic invasive lobular and ductal carcinoma. JAMA Network Open. e-Pub 2025.
- Shin-Cho LJ, Choi E, Dawkins-Moultin L, Wong CCY, Borjas M, Fei F, Xu Y, Chen M, Barcenas CH, Li Y, Lu Q. Feasibility and acceptability of an online expressive writing intervention for rural breast cancer survivors: A randomized controlled trial. Eur J Oncol Nurs 74:102790, 2025. e-Pub 2025. PMID: 39813977.
- Yennurajalingam S, Valero V, Smalgo BG, Overman MJ, Dasari A, Wolff RA, Raghav KPS, Barcenas CH, Busaidy NL, Fellman B, Basen-Engquist K, Hess KR, Tripathy D, Bruera E. Physical Activity and Dexamethasone for Cancer-Related Fatigue: A Preliminary Placebo-Controlled, Randomized, Double-Blind Trial. J Natl Compr Canc Netw 23(1), 2025. e-Pub 2025. PMID: 39773433.
- Barcenas CH. Feasibility and Acceptability of an Online Expressive Writing Intervention for Rural Breast Cancer Survivors: A Randomized Controlled Trial European Journal of Oncology Nursing. European Journal of Oncology Nursing. e-Pub 2025.
- Raghavendra AS, Zakon DB, Jin Q, Strahan A, Grimm M, Hughes ME, Cherian M, Vincuilla J, Parker T, Tarantino P, Mittendorf EA, King TA, Valero V, Tripathy D, Tolaney SM, Tayob N, Lin NU, Stover DG, Barcenas CH, Garrido-Castro AC. Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy according to HER2-low status☆. ESMO Open 9(11):103973, 2024. e-Pub 2024. PMID: 39500139.
- Reddy JP, Sherry AD, Fellman B, Liu S, Bathala T, Haymaker C, Cohen L, Smith BD, Ramirez D, Shaitelman SF, Chun SG, Medina-Rosales M, Teshome M, Brewster A, Barcenas CH, Reuben A, Ghia AJ, Ludmir EB, Weed D, Shah SJ, Mitchell MP, Woodward WA, Gomez DR, Tang C. Adding Metastasis-Directed Therapy to Standard-of-Care Systemic Therapy for Oligometastatic Breast Cancer (EXTEND): a Multicenter, Randomized Phase II Trial. Int J Radiat Oncol Biol Phys, 2024. e-Pub 2024. PMID: 39486645.
- Shin-Cho LJ, Dawkins-Moultin L, Choi E, Chen M, Barcenas CH, Roth M, Li Y, Lu Q. Feasibility Trial of an Online Expressive Writing Intervention for Young Adult Cancer Survivors. J Adolesc Young Adult Oncol, 2024. e-Pub 2024. PMID: 39466058.
- Jayan A, Sukumar JS, Fangman B, Patel T, Raghavendra AS, Liu D, Pasyar S, Rauch R, Basen-Engquist K, Tripathy D, Wang Y, Khan SS, Barcenas CH. Real-World Immune-Related Adverse Events in Patients With Early Triple-Negative Breast Cancer Who Received Pembrolizumab. JCO Oncol Pract:OP2400371, 2024. e-Pub 2024. PMID: 39388649.
- Chen JH, Addanki S, Roy D, Bassett R, Kalashnikova E, Spickard E, Kuerer HM, Meas S, Sarli VN, Korkut A, White JB, Rauch GM, Tripathy D, Arun BK, Barcenas CH, Yam C, Sethi H, Rodriguez AA, Liu MC, Moulder SL, Lucci A. Monitoring response to neoadjuvant chemotherapy in triple negative breast cancer using circulating tumor DNA. BMC Cancer 24(1):1016, 2024. e-Pub 2024. PMID: 39148033.
- Singareeka Raghavendra A, Liu D, Shen Y, Barcenas CH, Ueno NT, Giordano S, Tripathy D, Sri Karuturi M. Outcomes of older adults with early-stage triple-negative breast cancer (TNBC) receiving chemotherapy: a single-institution experience. Breast Cancer Res Treat 207(1):81-90, 2024. e-Pub 2024. PMID: 38916821.
- George GC, Andersen C, Tang X, Rodriguez E, Jafry M, Swartz MC, Ahmed S, Barcenas CH, Livingston JA, Roth ME, Hildebrandt MAT. Patient-Reported Quality of Life at Diagnosis in Adolescent and Young Adults With Cancer. J Natl Compr Canc Netw:1-8. e-Pub 2024. PMID: 38996438.
- Cho D, Roth M, Peterson SK, Jennings K, Kim S, Weathers SP, Ahmed S, Livingston JA, Barcenas C, You YN, Milbury K. Associations Between Stress, Health Behaviors, and Quality of Life in Young Couples During the Transition to Survivorship: Protocol for a Measurement Burst Study. JMIR Res Protoc 13:e53307, 2024. e-Pub 2024. PMID: 38652520.
- Woodfin AA, Yam C, Teshome M, Kuerer HM, Hunt KK, Meric-Bernstam F, Schaverien M, Barcenas CH, Sun SX. Axillary Nodal Metastases Conversion and Perioperative Complications with Neoadjuvant Pembrolizumab Therapy in Triple Negative Breast Cancer. Ann Surg Oncol 31(2):974-980, 2024. e-Pub 2024. PMID: 37973647.
- Sinha, A, Moyé, LA, Piller, LB, Yamal, JM, Barcenas, CH, Song, J, Davis, B. Simultaneous population enrichment and endpoint selection in phase 3 randomized controlled trials. Communications in Statistics - Theory and Methods 53(10):3728-3741, 2024. e-Pub 2024.
- Prinsloo S, Kaptchuk TJ, De Ridder D, Lyle R, Bruera E, Novy D, Barcenas CH, Cohen LG. Brain-computer interface relieves chronic chemotherapy-induced peripheral neuropathy: A randomized, double-blind, placebo-controlled trial. Cancer 130(2):300-311, 2024. e-Pub 2024. PMID: 37733286.
- Jayan, A, Singareeka Raghavendra, A, Bassett Jr, R, Barcenas, CH. Bone-Targeted Therapy Regimen and Skeletal-Related Events in Patients Surviving Longer Than 2 Years With Metastatic Breast Cancer and Bone Metastasis. Clinical breast cancer 23(8):e515-e522, 2023. e-Pub 2023. PMID: 37735019.
- Chido-Amajuoyi OG, Onyeaka HK, Sokale IO, Nwani S, Barcenas CH, Amonoo HL, Shete S. Political Ideology and Trust in Government Health Agencies for Cancer Information. JAMA Netw Open 6(11):e2341191, 2023. e-Pub 2023. PMID: 37921773.
- Chido-Amajuoyi OG, MD, MPH, Onyeaka HK, MD, MPH, Sokale IO, MD, DrPH, Nwani S, BS, Barcenas CH, MD, Amonoo HL, MD, MPP, Shete S, PhD. Political Ideology and Trust in Government Health Agencies for Cancer Information. JAMA. e-Pub 2023.
- Prinsloo S, Kaptchuk TJ, Ridder D, Lyle R, Bruera E, Novy D, Barcenas CH, Cohen LG. Brain-computer Interface Relieves Chronic Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-blind, Placebo-controlled Trial. CANCER, 2023. e-Pub 2023.
- Jayan A, Raghavendra AS, Bassett R, Barcenas CH. Bone-Targeted Therapy Regimen and Skeletal-Related Events in Patients Surviving Longer than 2 Years with Metastatic Breast Cancer and Bone Metastasis. Clinical Breast Cancer, 2023. e-Pub 2023.
- Gandhi A, Xu T, DeSnyder SM, Smith GL, Lin R, Barcenas CH, Stauder MC, Hoffman KE, Strom EA, Ferguson S, Smith BD, Woodward WA, Perkins GH, Mitchell MP, Garner D, Goodman CR, Aldrich M, Travis M, Lilly S, Bedrosian I, Shaitelman SF. Prospective, early longitudinal assessment of lymphedema-related quality of life among patients with locally advanced breast cancer: The foundation for building a patient-centered screening program. Breast 68:205-215, 2023. e-Pub 2023. PMID: 36863241.
- Chan A, Ruiz-Borrego M, Marx G, Chien AJ, Rugo HS, Brufsky A, Thirlwell M, Trudeau M, Bose R, García-Sáenz JA, Egle D, Pistilli B, Wassermann J, Cheong KA, Schnappauf B, Semsek D, Singer CF, Foruzan N, DiPrimeo D, McCulloch L, Hurvitz SA, Barcenas CH. Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer. Breast 67:94-101, 2023. e-Pub 2023. PMID: 36702070.
- Abraham A, Barcenas CH, Bleicher RJ, Cohen AL, Javid SH, Levine EG, Lin NU, Moy B, Niland JC, Wolff AC, Hassett MJ, Asad S, Stover DG. Clinicopathologic and sociodemographic factors associated with late relapse triple negative breast cancer in a multivariable logistic model: A multi-institution cohort study. Breast 67:89-93, 2023. e-Pub 2023. PMID: 36681001.
- Aldrich MB, Rasmussen JC, DeSnyder SM, Woodward WA, Chan W, Sevick-Muraca EM, Mittendorf EA, Smith BD, Stauder MC, Strom EA, Perkins GH, Hoffman KE, Mitchell MP, Barcenas CH, Isales LE, Shaitelman SF. Prediction of breast cancer-related lymphedema by dermal backflow detected with near-infrared fluorescence lymphatic imaging. Breast Cancer Res Treat 195(1):33-41, 2022. e-Pub 2022. PMID: 35816269.
- Kalra M, Henry E, McCann K, Karuturi MS, Bustamante Alvarez JG, Barcenas C. Making National Cancer Institute-Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational Study. JMIR Cancer. e-Pub 2022.
- Kalra, M, Henry, E, McCann, K, Karuturi, MS, Bustamante Alvarez, JG, Parkes, A, Wesolowski, R, Wei, M, Mougalian, SS, Durm, GA, Qin, A, Schonewolf, CA, Trivedi, M, Armaghani, A, Wilson, FH, Iams, WT, Turk, AA, Vikas, P, Cecchini, M, Lubner, SJ, Pathak, P, Spencer, K, Koshkin, VS, Labriola, MK, Marshall, CH, Beckermann, KE, Sharifi, MN, Bejjani, AC, Hotchandani, V, Housri, S, Housri, N, Soliman, H, Tripathy, D, Hershman, D, Otterson, GA, Ramaswamy, B, Carbone, DP, Jalal, SI, Hanna, N, Kalinsky, K, Tevaarwerk, AJ, Barcenas, CH, Wisinski, KB, Lustberg, MB, Horn, L, Crew, KD, Owen, D, Lim, B, Arun, BK, Ueno, NT. Making National Cancer Institute–Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board. JMIR Cancer 8(2), 2022. e-Pub 2022. PMID: 35588361.
- Wu LR, Dai P, Wang MX, Chen SX, Cohen EN, Jayachandran G, Zhang JX, Serrano AV, Xie NG, Ueno NT, Reuben JM, Barcenas CH, Zhang DY. Ensemble of Nucleic Acid Absolute Quantitation Modules for Copy Number Variation Detection and RNA Profiling. Nat Commun 13(1791 (2022)):1791, 2022. e-Pub 2022. PMID: 35379811.
- Singareeka Raghavendra A, Kypriotakis G, Karam-Hage M, Kim S, Jizzini M, Seoudy KS, Robinson JD, Barcenas CH, Cinciripini PM, Tripathy D, Ibrahim NK. The Impact of Treatment for Smoking on Breast Cancer Patients' Survival. Cancers (Basel) 14(6), 2022. e-Pub 2022. PMID: 35326615.
- Barcenas CH, Song J, Murthy R, Raghavendra AS, Li Y, Hsu L, Carlson RW, Tripathy D, Hortobagyi G. Reply to Letter to Editor: Systematic Bias in Medical Algorithms: to include or not include Discriminatory Information?. JCO Clinical Cancer Informatics, 2022. e-Pub 2022.
- Diao K, Andring LM, Barcenas CH, Singh P, Carisa Le-Petross H, Reed VK, Reddy JP, Bloom ES, Ahmad NR, Mayo LL, Perkins GH, Mitchell MP, Nead KT, Tereffe W, Smith BD, Woodward WA. Contemporary Outcomes After Multimodality Therapy in Patients With Breast Cancer Presenting With Ipsilateral Supraclavicular Node Involvement. Int J Radiat Oncol Biol Phys 112(1):66-74, 2022. e-Pub 2022. PMID: 34710521.
- Jackisch C, Barcenas CH, Bartsch R, Palma JD, Glück S, Harbeck N, Macedo G, O'Shaughnessy J, Pistilli B, Ruiz-Borrego M, Rugo HS. Optimal strategies for successful initiation of neratinib in patients with HER2-positive breast cancer. Clin Breast Cancer 21(5):e575-e583, 2021. e-Pub 2021. PMID: 33678567.
- Dumbrava EE, Call SG, Huang HJ, Stuckett AL, Madwani K, Adat A, Hong DS, Piha-Paul SA, Subbiah V, Karp DD, Fu S, Naing A, Tsimberidou AM, Moulder SL, Koenig KH, Barcenas CH, Kee BK, Fogelman DR, Kopetz ES, Meric-Bernstam F, Janku F. PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers. ESMO Open 6(5):100230, 2021. e-Pub 2021. PMID: 34479035.
- Elmore LC, Kuerer HM, Barcenas CH, Smith BD, Miggins MV, Lucci A, Caudle AS, Meric-Bernstam F, Hunt KK, Teshome M. Clinical Course of Breast Cancer Patients with Local-Regional Progression During Neoadjuvant Systemic Therapy. Ann Surg Oncol 28(10):5477-5485, 2021. e-Pub 2021. PMID: 34247335.
- Diao K, Andring LM, Barcanas, C H, Singh, Le-Petross, H, Reed, V K, Reddy, J P, Bloom, E, Ahmad, N R, Mayo, L L, Perkins, G H, Mitchell, M P, Tereffe, W. Contemporary Outcomes after Multimodality Therapy in Breast Cancer Patients Presenting with Ipsilateral Supraclavicular Node Involvement. Red Journal (IJROBP), 2021. e-Pub 2021.
- Barcenas CH, Song J, Murthy RK, Raghavendra AS, Li Y, Hsu L, Carlson RW, Tripathy D, Hortobagyi GN. Prognostic Model for De Novo and Recurrent Metastatic Breast Cancer. JCO Clin Cancer Inform 5:789-804, 2021. e-Pub 2021. PMID: 34351787.
- Singareeka Raghavendra A, Alameddine HF, Andersen CR, Selber JC, Brewster AM, Barcenas CH, Caudle AS, Arun BK, Tripathy D, Ibrahim NK. Influencers of the decision to undergo contralateral prophylactic mastectomy among women with unilateral breast cancer. Cancers (Basel) 13(9), 2021. e-Pub 2021. PMID: 33922702.
- Asad S, Barcenas CH, Bleicher RJ, Cohen AL, Javid SH, Levine EG, Lin NU, Moy B, Niland J, Wolff AC, Hassett MJ, Stover DG. Socio demographic factors associated with rapid relapse in triple-negative breast cancer: A multi-institution study. J Natl Compr Canc Netw:1-8. e-Pub 2021. PMID: 33691275.
- Chun YS, Mizuno T, Cloyd JM, Ha MJ, Omichi K, Tzeng CD, Aloia TA, Ueno NT, Kuerer HM, Barcenas CH, Vauthey JN. Hepatic resection for breast cancer liver metastases: Impact of intrinsic subtypes. Eur J Surg Oncol 46(9):1588-1595, 2020. e-Pub 2020. PMID: 32253074.
- de Melo Gagliato D, Lei X, Giordano SH, Valero V, Barcenas CH, Hortobagyi GN, Chavez-MacGregor M. Impact of delayed neoadjuvant systemic chemotherapy on overall survival among breast cancer patients. Oncologist 25(9):749-757, 2020. e-Pub 2020. PMID: 32431013.
- Barcenas CH, Hurvitz SA, Di Palma JA, Bose R, Chien AJ, Iannotti N, Marx G, Brufsky A, Litvak A, Ibrahim E, Alvarez RH, Ruiz-Borrego M, Chan N, Manalo Y, Kellum A, Trudeau M, Thirlwell M, Garcia Saenz J, Hunt D, Bryce R, McCulloch L, Rugo HS, Tripathy D, Chan A, Investigators CS. Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: CONTROL Trial. Ann Oncol 31(9):1223-1230, 2020. e-Pub 2020. PMID: 32464281.
- Berkman A, Livingston JD, Merriman JK, Hildebrandt M, Wang J, Dibaj SS, McQuade JL, You JQN, Ying AK, Barcenas CH, Bodurka E, Depombo A, Lee HJ, dee Grut JF, Roth M. Long-term survival among 5 years survivors of adolescent and young adult cancer. Cancer, 2020. e-Pub 2020.
- Montoya-Restrepo M, Barcenas CH, Gomez-Wolf R, Cock-Rada A, Castano-Vasquez M, Garcia-Garcia H. Survival of young women with breast cancer in a Colombian referral Cancer Center between 2007-2016. Rev Col Hematol Oncol 7(1):26-32, 2020. e-Pub 2020.
- Litton JK, Scoggins ME, Hess KR, Adrada BE, Murthy RK, Damodaran S, DeSnyder SM, Brewster AM, Barcenas CH, Valero V, Whitman GJ, Schwartz-Gomez J, Mittendorf EA, Thompson AM, Helgason T, Ibrahim N, Piwnica-Worms H, Moulder SL, Arun BK. Neoadjuvant Talazoparib for patients with operable breast cancer with a germline BRCA pathogenic variant. J Clin Oncol 38(5):JCO1901304, 2020. e-Pub 2020. PMID: 31461380.
- George GC, PhD, Andersen C, MS, Tang X, PhD, Rodriguez E, BS, Jafry M, BS, Swartz MC, PhD, Ahmed S, MD, Barcenas CH, MD, Livingston J, MD, Roth ME, MD, Hildebrandt MA, PhD. Patient-Reported Quality of Life at Diagnosis in Adolescent and Young Adult Cancer Patients. JNCCN - Journal of the National Comprehensive Cancer Network.
- Sun S, Man X, Zhou D, Zang F. The metastasis patterns and their prognostic features in patients with de novo metastatic breast cancer of different ages. Cancer Medicine.
Other Articles
- Hooda Z, Lu Y, Mehran RJ, Moran C, Barcenas CH Rosai-Dorfman Disease Mimicking Metastasis to the Spleen From Breast Cancer. Clin Nucl Med 50(5):450-451, 2025. PMID: 40179297.
- Abdelgadir O, Hussain MR, Hollis-Hansen K, Barcenas CH, Kuo Y, Skinner CS, Cowell LG, Messiah SE, Lopez DS Anti-obesity medications and risk of obesity-related cancers in older.
- Barcenas CH Stratifying Risk for Trastuzumab-Induced Cardiac Dysfunction: Towards Personalized Surveillance Protocols, 2025.
- Raghavendra A, Zakon D, Jin Q, Strahan A, Grimm M, Hughes M, Cherian M, Vincuilla J, Parker T, Tarantino P, Mittendorf E, King T, Valero V, Tripathy D, Tolaney S, Tayob N, Lin N, Stover D, Barcenas C, Garrido-Castro A Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy according to HER2-low status. ESMO Open, 2024.
- Barcenas CH Physical Activity with Dexamethasone for Cancer related fatigue. JNCCN.
Editorials
- Barcenas CH. Adding Metastasis-Directed Therapy to Standard-of-Care Systemic Therapy for Oligometastatic Breast Cancer (EXTEND): a Multicenter, Randomized Phase II Trial. International Journal of Radiation Oncology, Biology, Physics ROB 29069, 2024.
- Barcenas CH. Feasibility Trial of an Online Expressive Writing Intervention for Young Adult Cancer Survivors. Journal of Adolescent and Young Adult Oncology.
Abstracts
- Sarah Asad MPH, Carlos H Barcenas MD, MS, Richard J Bleicher MD, Adam L Cohen MD, MS, Sara H Javid MD, Ellis G Levine MD, Nancy U Lin MD, Beverly Moy MD, MPH, PhD JN, Antonio C Wolff MD, Michael J Hassett MD, MPH, and Daniel G Stover MD. Sociodemographic Factors Associated With Rapid Relapse in Triple-Negative Breast Cancer: A Multi-Institution Study. JNCCN 19(7), 2021. e-Pub 2021.
- Barcenas CH, Melo Gagliato DD, Lei X, Giordano SH, Valero V. Impact of Delayed Neoadjuvant Systemic Chemotherapy on Overall Survival Among Patients with Breast Cancer. The Oncologist 25(9):749-757, 2020. e-Pub 2020.
- Barcenas CH, Olek E, Hunt D, Tripathy D, Ibrahim E, Wilkinson M, Hurvitz S, Iannotti N, Kellum A, Manalo Y, Wong S, Hansen V, Alvarez RH, Chan A, Gore I, Kendall SD, Wade JL, Ruiz R, Fang P, Bryce R, Moran S. Incidence and severity of diarrhea with neratinib + intensive loperamide prophylaxis in patients with HER2+ early-stage breast cancer: Interim analysis from the multicenter, open-label, phase II control trial. Cancer Res.
Book Chapters
- Barcenas CH, Brewster AM. Overview of breast cancer survivorship management guidelines. In: Breast Cancer. 3rd. Springer.
Letters to the Editor
- Barcenas CH, Song J, Murthy RK, Raghavendra AS, Li Y, Hsu L, Carlson RW, Tripathy D, Hortobagyi GN. Reply to A. Pfob and C. Sidey-Gibbons. JCO Clin Cancer Inform 6: e2100171, 2022.
Selected Presentations & Talks
Local Presentations
- 2025. MRD in Early Breast Cancer. Baptist MD Anderson Oncology Grand Rounds. Houston, Texas, US.
- 2023. Blood-based biomarkers in breast cancer. Conference. MD ANDERSON CANCER CENTER. Houston, TX, US.
- 2021. Updates on staging and oncology history. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2021. Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2020. ESMO Review: ASCENT Trial. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2020. Association of ctDNA with disease recurrence among patients with non-metastatic TNBC who receive adjuvant capecitabine. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2020. Controversies in genomic testing in breast cancer. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2019. Multiplexed enrichment of rare DNA variants via sequence-selective and temperature-robust amplification. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2019. Early therapeutic intervention in early-stage breast cancer patients with minimal relapse detected via molecular surveillance. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2019. Genomic assays in node-positive, HR+ HER2-negative BC: A debate. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2018. Persephone trial: 6 versus 12 months of adjuvant trastuzumab in patients with HER2 positive early breast cancer: Randomized phase 3 non-inferiority trial with definitive 4-year disease-free survival results. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2018. Circulating tumor cells five years after diagnosis are prognostic for late recurrence in operable stage II-III breast cancer. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2018. Early therapeutic intervention in early-stage breast cancer patients with minimal relapse detected via molecular surveillance. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2018. Integrating no surgery trials at MD Anderson. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2017. Long term side effects of breast cancer treatment. Conference. Susan G. Komen Foundation. Houston, TX, US.
- 2017. Molecular surveillance in early stage breast cancer. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2017. Neratinib in the adjuvant setting for HER2-positive breast cancer patients. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2017. Research integrity. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2017. Updates in breast cancer survivorship research, with a focus on outcomes and surveillance. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2017. Staging and oncological history in EPIC. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2017. Presented poster, Determinants of weight during adjuvant endocrine therapy (ET) and association with recurrence in long-term breast cancer (BC) survivors. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2017. Presented poster, Early therapeutic intervention in early-stage breast cancer (ESBC) patients with minimal residual disease detected via molecular surveillance. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2017. Updates in genetic counseling and testing in breast cancer survivors. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2016. San Antonio Breast Cancer Symposium updates on survivorship. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2016. DCIS: Medical oncology perspectives and issues. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2016. Extended adjuvant endocrine therapy in breast cancer. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2016. The use of genomic assays in our MD Anderson clinical practice. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2016. Presented poster, Association between mammographic breast density and the development of a second contralateral breast cancer: A nested case-control study. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2014. Recommendations for surveillance of breast cancer survivors. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2014. Overuse of diagnostic imaing for early stage breast cancer. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2012. Toxicities of chemotherapy regimens used in early breast cancer. Conference. CERCIT (Comparative Effectiveness Research on Cancer in Texas). Houston, TX, US.
- 2011. Transfusion medicine interesting cases from ASH Dashboard. Conference. Citywide. Houston, TX, US.
- 2011. Pure red cell aplasia. Conference. Citywide. Houston, TX, US.
Regional Presentations
- 2019. Presented Poster: Effect of prophylaxis or neratinib dose escalation on neratinib-associated diarrhea and tolerability inpatients with HER2-positive early-stage breast cancer: Phase II CONTROL trial. Conference. UT Health Science Center. San Antonio, TX, US.
- 2016. Presented poster, Incidence and severity of diarrhea with neratinib + intensive loperamide prophylaxis in patients with HER2+ early-stage breast cancer: Interim analysis from the multicenter, open-label, phase II control trial. Conference. UT Health Science Center. San Antonio, TX, US.
National Presentations
- 2018. Challenging cases in the management of breast cancer. Invited. 2018 ASTRO Annual Meeting. San Antonio, TX, US.
International Presentations
- 2022. Update on Immunotherapy in Breast Cancer. Invited. XXI Colombian Cancer Congress. Medellin, CO.
- 2019. Update in hormone receptor positive breast cancer. Invited. 6th ACHO National Update Breast Cancer Congress. Barranquilla, CO.
- 2019. What's new in HER2 positive breast cancer. Invited. 6th ACHO National Update Breast Cancer Congress. Barranquilla, CO.
- 2019. Triple negative breast cancer: Treatment in 2019. Invited. 6th ACHO National Update Breast Cancer Congress. Barranquilla, CO.
- 2019. Long-term survival outcomes of triple-negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity. Invited. 3rd Cali Breast Meeting. Cali, CO.
- 2019. Challenges for long-term survival in breast cancer. Invited. 3rd Cali Breast Meeting. Cali, CO.
- 2019. Importance of genetic counseling in surviving patients with breast cancer. Invited. 3rd Cali Breast Meeting. Cali, CO.
- 2019. Presented Poster: Effect of prophylaxis on neratinib-associated diarrhea in patients with HER2+ early-stage breast cancer: Phase II CONTROL trial. Invited. Annual ASCO Meeting. Chicago, US.
- 2018. Can genomic signatures be used for the selection of system treatment in young patients with breast cancer?. Invited. 36th National Oncology Congress. Guadalajara, MX.
- 2018. When can I skip double hormonal blockage in premenopausal patients with hormone sensitive breast cancer?. Invited. 36th National Oncology Congress. Guadalajara, MX.
- 2018. Current evidence based management of stage I-III breast cancer patients. Invited. Hematology and Medical Oncology Association Annual Meeting. San Juan, PR.
- 2018. Current evidence-based management of metastatic breast cancer. Invited. Hematology and Medical Oncology Association Annual Meeting. San Juan, PR.
- 2018. Breast Cancer. Invited. Post ASCO Review 2018. San Juan, PR.
- 2016. Controversy and debate: Additional chemotherapy for high risk/residual disease?. Invited. GAP Educational Program with National Cancer Center Institute of Dominician Republic (INCART). Santo Domingo, DO.
- 2016. Molecular profiling vs. standard biomarkers: Which is best in decisions about adjuvant systemic therapy. Invited. GAP Educational Program with National Cancer Center Institute of Dominician Republic (INCART). Santo Domingo, DO.
- 2016. Management of long term effects and surveillance for breast cancer survivors. Invited. GAP Educational Program with National Cancer Center Institute of Dominician Republic (INCART). Santo Domingo, DO.
- 2016. Best of ASCO: Breast cancer HER2/ER+/triple negative cytotoxic chemotherapy. Invited. Best of ASCO Meeting. Panama City, PA.
- 2016. Presented poster: Outcomes after chemotherapy in early-stage breast cancer (EBC) patients who underwent a 21-gene expression assay. Invited. Annual ASCO Meeting. Chicago, US.
- 2016. Presented poster: Association between tumor stage of first non-metastatic breast cancer and second contralateral breast cancer. Invited. Cancer Survivorship Symposium: Advancing Care and Research. San Francisco, US.
- 2015. Survivorship in breast cancer. Who should do follow-up?. Invited. Past, Present and Future Breast Cancer Treatment Symposium. Medellin, CO.
- 2015. Breast cancer brain metastases in HER2 positive disease: The medical oncology point of view. Invited. Past, Present and Future of Breast Cancer Treatment Symposium. Medellin, CO.
- 2015. Presented poster, Hormonal treatment and late recurrence in early-stage breast cancer patients. Invited. ASCO Annual Meeting. Chicago, US.
- 2013. Presented poster, Off-label prescribing of chemotherapy among older cancer patients. Invited. ASCO Annual Meeting. Chicago, US.
- 2012. Presented poster, Survival outcomes in HER2-positive invasive lobular breast carcinoma. Invited. ASCO Annual Meeting. Chicago, US.
- 2011. Presented poster, Anthracycline adherence in older patients with breast cancer. Invited. ASCO Annual Meeting. Chicago, US.
Grant & Contract Support
| Date: | 2023 - 2028 |
| Title: | Validation of Serum Biomarkers for Race-Specific Breast Cancer Recurrence |
| Funding Source: | NIH flow thru Henry M Jackson |
| Role: | Co-I |
| Date: | 2023 - Present |
| Title: | Detection of minimal residual disease (MR) in patients with breast cancer using a highly sensitive liquid biopsy platform and its association with clinical outcomes |
| Funding Source: | Personalis, Inc |
| Role: | PI |
| ID: | 2022-0837 |
| Date: | 2023 - 2026 |
| Title: | Recurrence-specific biomarkers on Disparities in the Aggressiveness of Breast Cancer |
| Funding Source: | DoD flow thru Henry M Jackson |
| Role: | Co-I |
| Date: | 2023 - Present |
| Title: | B-STRONGER-I |
| Funding Source: | Personalis |
| Role: | PI |
| ID: | 2023-1064 |
| Date: | 2022 - 2025 |
| Title: | TrAstuzumab Cardiomyopathy Therapeutic Intervention with Carvedilol (TACTIC) Trial |
| Funding Source: | Mayo Clinic |
| Role: | Investigator |
| Date: | 2022 - 2024 |
| Title: | Detection by circulating RNA with OPtimized machine LEarning Technology for Breast Cancer |
| Funding Source: | Preferred Medicine Inc |
| Role: | PI |
| ID: | 2020-0724 |
| Date: | 2020 - 2027 |
| Title: | DROPLET-BRC study |
| Funding Source: | Preferred Medicine, Inc |
| Role: | PI |
| ID: | 2020-0724 |
| Date: | 2019 - 2022 |
| Title: | Atorvastatin in triple-negative breast cancer (TNBC) patients who did not achieve a pathologic complete response (pCR) after receiving neoadjuvant chemotherapy |
| Funding Source: | IBC Network Foundation |
| Role: | PI |
| Date: | 2017 - 2021 |
| Title: | Calabresi Clinical Oncology Scholar K12 Award (Clinical Investigator Program) |
| Funding Source: | Paul Calabresi Clinical Oncology |
| Role: | PI |
| ID: | K12CA088084 |
| Date: | 2016 - 2023 |
| Title: | An Open-Label to Characterize the Incidence and Severity of Diarrhea in Patients with Early-Stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis |
| Funding Source: | Puma Biotechnology, Inc |
| Role: | PI |
| ID: | 2015-1122 |
| Date: | 2013 - 2015 |
| Title: | CERCIT Scholar in the comparative effectiveness research on cancer in Texas (CERCIT) Training Program |
| Funding Source: | CERCIT |
| Role: | PI |
| ID: | 00001717 |
| Date: | 2011 - 2013 |
| Title: | T32 Academic Fellowship training grant for academic years 2011 through 2013 |
| Funding Source: | NIH/NCI |
| Role: | Trainee |
| ID: | 5 T32 CA009666 |
| Title: | LEADER |
| Funding Source: | Novartis |
| Role: | PI |
| ID: | 2023-0428 |
Patient Reviews
CV information above last modified May 07, 2025